SiVIEW, a specialist in AI-driven visual diagnostics, announces with LBO France a capital increase of €5.5M
The funds will allow the acceleration of SiVIEW’s growth and R&D roadmap with the ambition of revolutionizing visual health care.
SiVIEW is a French start-up which has developed a unique artificial intelligence technology that enables reliable, accurate, and fast eye examinations to be performed. This can be delegated by the healthcare professional in order to focus on the patient and optimize the overall care plan. SiVIEW announces that it has raised €5.5M in a Series A round with LBO France’s Digital Health 2 fund to accelerate its global expansion and R&D roadmap.
While the need for reliable visual diagnostics is constantly increasing (e.g., due to a pandemic of myopia, increased screen-time, and an aging population), the number of experts able to perform the required examinations is decreasing, and SiVIEW has designed a disruptive innovation that allows quick and easy eye examinations, that are both precise and detailed, to be performed intuitively to support diagnosis and prescription.
Founded by vision specialists, SiVIEW addresses a global health issue: to obtain the correct prescription simply and quickly, regardless of the complexity of the visual profile.
Marketed after 6 years of R&D, the SiviewExam® solution is compatible with almost all optical equipment on the market and offers quality results (measurements and reports) in less than 8 minutes. It supports the decision-making process, allowing the vision expert to save time and improve efficiency for better patient care. The solution is already used in many European countries and is experiencing a strong growth phase that will accelerate with access to the North American and Asian markets.
Just a few days before two major industry trade shows, ESCRS in Milan and SILMO in Paris, SiVIEW has completed this fundraising to:
- Accelerate its international growth by increasing its investments in sales, marketing, and R&D (e.g., new testing and analysis modules, enhanced instrument interconnectivity, new innovation techniques);
- Position the company as a key player in the management of visual disorders worldwide.
Laure Pichereau, CEO & Co-founder of SiVIEW: “Our ambition from the beginning was to become the reference in artificial intelligence-driven eye exams. Once the SiVIEW solution was ready for commercialization, we received the support of major optical and ophthalmology chains in France and abroad. We are honored to welcome LBO France, leading specialist in digital health, as an investor and partner. I am personally very pleased with the trusting relationship that we have built together and which will enable us to work efficiently in this new phase of growth. I would also like to thank our historical investors, CARENCEAU and FIME, for their unwavering support since they joined the capital structure in 2018.”
Franck Noiret, Managing Director of LBO France: “We are very pleased to partner with SiVIEW and its founders who are recognized experts in the field. With its dual expertise in AI and optometry, SiVIEW has developed a unique software solution based on an intelligent and intuitive algorithm that automates eye exams and improves patient care. Commercialized in SaaS mode, the SiVIEW solution is aimed at the global market. This is the 7th investment of our Digital Health 2 fund, which is dedicated to financing innovative digital health companies in Europe. We are delighted to support them in their ambitious international development.”